Rapport Therapeutics, Inc. (RAPP)Healthcare | Biotechnology | Boston, United States | NasdaqGM
40.59 USD
-1.16
(-2.778%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 40.59 |
Hot Take ↕ | July 11, 2026, 5:48 a.m. EDT
The investment case for Rapport Therapeutics is severely compromised by a deteriorating business trajectory and a lack of shareholder returns. Fundamentally, the company is burning significant cash with negative operating margins and no revenue growth, while trading at a premium valuation relative to sales. The price action confirms this distress, having lost nearly 44% of its value over the last year. Crucially, the company has not paid a dividend in five years, offering no income buffer to offset the capital loss. While the Russell index addition provides some liquidity, the options market is screaming caution, with traders stacking heavy put positions to hedge against further drops. This is a speculative biotech play with no safety margin, making it unsuitable for investors seeking stability or income. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.052655 |
| MSTL | 0.054795 |
| AutoETS | 0.061303 |
| AutoARIMA | 0.065019 |
| MSTL_52 | 0.079804 |
| MSTL_52_75 | 0.127702 |
| MSTL_75 | 0.137906 |
Forecast horizon: 60 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 2.02 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.628 |
| Excess Kurtosis | -0.44 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.291 |
| Revenue per Share | 0.477 |
| Market Cap | 1,941,294,976 |
| Forward P/E | -9.23 |
| Beta | 0.95 |
| Website | https://www.rapportrx.com |
As of July 11, 2026, 5:48 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in out-of-the-money puts expiring in November and February compared to negligible call volume. While there is some call activity at strikes above the current price, the overwhelming capital allocation is in put writing or buying, suggesting a bearish bias and a fear of further declines rather than a bullish breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.8537252 |
| Address1 | 99 High Street |
| Address2 | Suite 2100 |
| All Time High | 43.76 |
| All Time Low | 6.43 |
| Ask | 51.26 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 602,790 |
| Average Daily Volume3 Month | 389,186 |
| Average Volume | 389,186 |
| Average Volume10Days | 602,790 |
| Beta | 0.948 |
| Bid | 29.61 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 9.863 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 40.59 |
| Current Ratio | 27.082 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 42.655 |
| Day Low | 39.7 |
| Debt To Equity | 2.291 |
| Display Name | Rapport Therapeutics |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | -121,206,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -12.172 |
| Enterprise To Revenue | 73.766 |
| Enterprise Value | 1,475,316,096 |
| Eps Current Year | -3.46429 |
| Eps Forward | -4.3975 |
| Eps Trailing Twelve Months | -2.6 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 37.7656 |
| Fifty Day Average Change | 2.8244019 |
| Fifty Day Average Change Percent | 0.07478769 |
| Fifty Two Week Change Percent | 185.37251 |
| Fifty Two Week High | 43.76 |
| Fifty Two Week High Change | -3.1699982 |
| Fifty Two Week High Change Percent | -0.07244054 |
| Fifty Two Week Low | 13.43 |
| Fifty Two Week Low Change | 27.16 |
| Fifty Two Week Low Change Percent | 2.022338 |
| Fifty Two Week Range | 13.43 - 43.76 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,717,767,000,000 |
| Float Shares | 31,782,429 |
| Forward Eps | -4.3975 |
| Forward P E | -9.230245 |
| Free Cashflow | -49,431,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 84 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.3428 |
| Gross Profits | 6,856,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04616 |
| Held Percent Institutions | 1.09531 |
| Implied Shares Outstanding | 47,826,929 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-06-07 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts. |
| Long Name | Rapport Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,941,294,976 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1828746377 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -107,277,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,998,687,362 |
| Number Of Analyst Opinions | 11 |
| Open | 41.12 |
| Operating Cashflow | -80,297,000 |
| Operating Margins | -1.21075 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 857 321 8020 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 40.59 |
| Post Market Time | 1,783,981,119 |
| Previous Close | 41.75 |
| Price Eps Current Year | -11.716687 |
| Price Hint | 2 |
| Price To Book | 4.115381 |
| Price To Sales Trailing12 Months | 97.06475 |
| Profit Margins | 0.0 |
| Quick Ratio | 26.644 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -1.16 |
| Regular Market Change Percent | -2.77844 |
| Regular Market Day High | 42.655 |
| Regular Market Day Low | 39.7 |
| Regular Market Day Range | 39.7 - 42.655 |
| Regular Market Open | 41.12 |
| Regular Market Previous Close | 41.75 |
| Regular Market Price | 40.59 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 357,207 |
| Return On Assets | -0.19103001 |
| Return On Equity | -0.2833 |
| Revenue Per Share | 0.477 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 47,826,929 |
| Shares Percent Shares Out | 0.0473 |
| Shares Short | 2,260,158 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 2,459,901 |
| Short Name | Rapport Therapeutics, Inc. |
| Short Percent Of Float | 0.0749 |
| Short Ratio | 5.61 |
| Source Interval | 15 |
| State | MA |
| Symbol | RAPP |
| Target High Price | 80.0 |
| Target Low Price | 40.0 |
| Target Mean Price | 56.63636 |
| Target Median Price | 56.0 |
| Total Cash | 476,782,016 |
| Total Cash Per Share | 9.969 |
| Total Debt | 10,803,000 |
| Total Revenue | 20,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.6 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 31.055225 |
| Two Hundred Day Average Change | 9.534775 |
| Two Hundred Day Average Change Percent | 0.30702642 |
| Type Disp | Equity |
| Volume | 357,207 |
| Website | https://www.rapportrx.com |
| Zip | 2,110 |